|
1
|
Liu FC, Lin HT, Kuo CF, See LC, Chiou MJ
and Yu HP: Epidemiology and survival outcome of breast cancer in a
nationwide study. Oncotarget. 8:16939–16950. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC
and Yen Y: Cancers in Taiwan: Practical insight from epidemiology,
treatments, biomarkers, and cost. J Formos Med Assoc.
119:1731–1741. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen YP, Lu YW and Yang CC: Breast cancer
trend in Taiwan. MOJ Womens Health. 6:1532017.
|
|
4
|
Rossi S, Cinini C, Di Pietro C, Lombardi
CP, Crucitti A, Bellantone R and Crucitti F: Diagnostic delay in
breast cancer: Correlation with disease stage and prognosis.
Tumori. 76:559–562. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang R, Li X, Zhang HM, Wang K and He JJ:
Cell-free circulating tumor DNA analysis for breast cancer and its
clinical utilization as a biomarker. Oncotarget. 8:75742–75755.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jafari SH, Saadatpour Z, Salmaninejad A,
Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H and Kianmehr
M: Breast cancer diagnosis: Imaging techniques and biochemical
markers. J Cell Physiol. 233:5200–5213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Mattos-Arruda L and Caldas C: Cell-free
circulating tumour DNA as a liquid biopsy in breast cancer. Mol
Oncol. 10:464–474. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seale KN and Tkaczuk KHR: Circulating
biomarkers in breast cancer. Clin Breast Cancer. Sep 22–2021.doi:
10.1016/j.clbc.2021.09.006 (Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Potter NT, Hurban P, White MN, Whitlock
KD, Lofton-Day CE, Tetzner R, Koenig T, Quigley NB and Weiss G:
Validation of a real-time PCR-based qualitative assay for the
detection of methylated SEPT9 DNA in human plasma. Clin Chem.
60:1183–1191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lamb YN and Dhillon S: Epi proColon
® 2.0 CE: A blood-based screening test for colorectal
cancer. Mol Diagn Ther. 21:225–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simon R and Roychowdhury S: Implementing
personalized cancer genomics in clinical trials. Nat Rev Drug
Discov. 12:358–369. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jones PA, Issa JP and Baylin S: Targeting
the cancer epigenome for therapy. Nat Rev Genet. 17:630–641. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Locke WJ, Guanzon D, Ma C, Liew YJ,
Duesing KR, Fung KYC and Ross JP: DNA methylation cancer
biomarkers: Translation to the clinic. Front Genet. 10:11502019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee TL, Leung WK, Chan MW, Ng EK, Tong JH,
Lo KW, Chung SC, Sung JJ and To KF: Detection of gene promoter
hypermethylation in the tumor and serum of patients with gastric
carcinoma. Clin Cancer Res. 8:1761–1766. 2002.PubMed/NCBI
|
|
16
|
Tang Q, Cheng J, Cao X, Surowy H and
Burwinkel B: Blood-based DNA methylation as biomarker for breast
cancer: A systematic review. Clin Epigenetics. 8:1152016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei KL, Chou JL, Chen YC, Low JT, Lin GL,
Liu JL, Chang TS, Chen WM, Hsieh YY, Yan PS, et al: Epigenetic
silencing of STAT3-targeted miR-193a, by constitutive activation of
JAK/STAT signaling, leads to tumor progression through
overexpression of YWHAZ in gastric cancer. Front Oncol.
11:5756672021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fackler MJ, Umbricht CB, Williams D,
Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P,
Visvananthan K, et al: Genome-wide methylation analysis identifies
genes specific to breast cancer hormone receptor status and risk of
recurrence. Cancer Res. 71:6195–6207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fleischer T, Frigessi A, Johnson KC,
Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg
F, Naume B, et al: Genome-wide DNA methylation profiles in
progression to in situ and invasive carcinoma of the breast with
impact on gene transcription and prognosis. Genome Biol.
15:4352014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jovanovic J, Ronneberg JA, Tost J and
Kristensen V: The epigenetics of breast cancer. Mol Oncol.
4:242–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu J, Wilfred P, Korbie D and Trau M:
Regulation of canonical oncogenic signaling pathways in cancer via
DNA methylation. Cancers (Basel). 12:31992020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tao S, Li H, Ma X, Lian B, He J, Gao Y and
Li J: Methylation-mediated silencing of MicroRNA-497 promotes
breast cancer progression through up-regulation of Mucin1. Front
Oncol. 10:5520992020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C, Zhao H, Li J, Liu H, Wang F, Wei
Y, Su J, Zhang D, Liu T and Zhang Y: The identification of specific
methylation patterns across different cancers. PLoS One.
10:e01203612015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Q and Maniatis T: A striking
organization of a large family of human neural cadherin-like cell
adhesion genes. Cell. 97:779–790. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hulpiau P and van Roy F: Molecular
evolution of the cadherin superfamily. Int J Biochem Cell Biol.
41:349–369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Serrano-Gomez SJ, Maziveyi M and Alahari
SK: Regulation of epithelial-mesenchymal transition through
epigenetic and post-translational modifications. Mol Cancer.
15:182016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zou D, Yoon HS, Perez D, Weeks RJ,
Guilford P and Humar B: Epigenetic silencing in non-neoplastic
epithelia identifies E-cadherin (CDH1) as a target for
chemoprevention of lobular neoplasia. J Pathol. 218:265–272. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Asiaf A, Ahmad ST, Aziz SA, Malik AA,
Rasool Z, Masood A and Zargar MA: Loss of expression and aberrant
methylation of the CDH1 (E-cadherin) gene in breast cancer patients
from Kashmir. Asian Pac J Cancer Prev. 15:6397–6403. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de Ruijter TC, van der Heide F, Smits KM,
Aarts MJ, van Engeland M and Heijnen VCG: Prognostic DNA
methylation markers for hormone receptor breast cancer: A
systematic review. Breast Cancer Res. 22:132020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chou JL, Huang RL, Shay J, Chen LY, Lin
SJ, Yan PS, Chao WT, Lai YH, Lai YL, Chao TK, et al:
Hypermethylation of the TGF-β target, ABCA1 is associated with poor
prognosis in ovarian cancer patients. Clin Epigenetics. 7:12015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF,
Chen Y, Wang X, Huang W, Tung CL, Chen GC, et al: Distinct DNA
methylation epigenotypes in bladder cancer from different Chinese
sub-populations and its implication in cancer detection using
voided urine. BMC Med Genomics. 4:452011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tseng KC, Chou JL, Huang HB, Tseng CW, Wu
SF and Chan MW: SOCS-1 promoter methylation and treatment response
in chronic hepatitis C patients receiving
pegylated-interferon/ribavirin. J Clin Immunol. 33:1110–1116. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wong CC, Xu J, Bian X, Wu JL, Kang W, Qian
Y, Li W, Chen H, Gou H, Liu D, et al: In colorectal cancer cells
with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA
demethylation to increase WNT signaling, stemness, and drug
resistance. Gastroenterology. 159:2163–2180.e6. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Teschendorff AE, Gao Y, Jones A, Ruebner
M, Beckmann MW, Wachter DL, Fasching PA and Widschwendter M: DNA
methylation outliers in normal breast tissue identify field defects
that are enriched in cancer. Nat Commun. 7:104782016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Du T, Liu B, Wang Z, Wan X and Wu Y: CpG
methylation signature predicts prognosis in breast cancer. Breast
Cancer Res Treat. 178:565–572. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Peng Y, Shui L, Xie J and Liu S:
Development and validation of a novel 15-CpG-based signature for
predicting prognosis in triple-negative breast cancer. J Cell Mol
Med. 24:9378–9387. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mao XH, Ye Q, Zhang GB, Jiang JY, Zhao HY,
Shao YF, Ye ZQ, Xuan ZX and Huang P: Identification of
differentially methylated genes as diagnostic and prognostic
biomarkers of breast cancer. World J Surg Oncol. 19:292021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chou JL, Chen LY, Lai HC and Chan MW:
TGF-β: Friend or foe? The role of TGF-β/SMAD signaling in
epigenetic silencing of ovarian cancer and its implication in
epigenetic therapy. Expert Opin Ther Targets. 14:1213–1223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bloushtain-Qimron N, Yao J, Snyder EL,
Shipitsin M, Campbell LL, Mani SA, Hu M and Chen H: Cell
type-specific DNA methylation patterns in the human breast. Proc
Natl Acad Sci USA. 105:14076–14081. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Novak P, Stampfer MR, Munoz-Rodriguez JL,
Garbe JC, Ehrich M, Futscher BW and Jensen TJ: Cell-type specific
DNA methylation patterns define human breast cellular identity.
PLoS One. 7:e522992012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Beltran-Garcia J, Osca-Verdegal R,
Mena-Molla S and Garcia-Gimenez JL: Epigenetic IVD tests for
personalized precision medicine in cancer. Front Genet. 10:6212019.
View Article : Google Scholar : PubMed/NCBI
|
